Navigation Links
Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Date:4/15/2008

Companies Also Sign Manufacturing and Distribution Agreement

GURGAON, India and PRINCETON, N.J., April 15 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has reached several agreements with AstraZeneca. Two of these agreements concern Esomeprazole magnesium capsules. The third agreement pertains to Omeprazole 40mg tablets, and the fourth agreement pertains to Felodipine ER capsules. All of the agreements are specific to the U.S. market.

The agreement settles the patent infringement litigation filed by AstraZeneca following Ranbaxy's submission to the United States Food & Drug Administration of an Abbreviated New Drug Application for a generic version of Esomeprazole magnesium. Under the settlement agreement, Ranbaxy concedes that all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable.

The settlement agreement will allow Ranbaxy to commence exclusive sales of a generic version of Nexium under a license from AstraZeneca on May 27, 2014. During the 180-day period following the date, RPI will distribute the only generic Esomeprazole magnesium product in the US market.

Ranbaxy has filed a Consent Judgment with the U.S. District Court for the District of New Jersey reflecting the terms of the settlement agreement. With the Court now having entered the Consent Judgment, the settlement agreement is final, and the patent infringement litigation against Ranbaxy has been dismissed.

Merck & Co., Inc., through KBI Inc. and KBI-E and under the terms of Merck's restructured partnership with AstraZeneca announced in 1998, has also entered into the settlement agreement.

"We are pleased with the agreement which will provide certainty as to the launch of a generic formulation of Esomeprazole magnesium in the US market," according to Malvinder M. Singh, CEO and Managing Director of Ranbaxy Laboratories Ltd.
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
4. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
5. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
6. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
8. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
9. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
10. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
11. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SoundConnect , an award ... proud to announce the strategic additions of implementation, ... Boston, Charleston and Atlanta offices. SoundConnect’s organizational ... for hosted solutions, collaboration and mobility that improve ... , SoundConnect was founded in 2004, with the ...
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... 29, 2014   Sequenom, Inc. (NASDAQ: ... innovative genetic analysis solutions, and Mayo Medical Laboratories ... in the United States , have ... and applications. "We have great appreciation for ... and we welcome the opportunity to partner with the ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4
... Enlarge and Worsen Over Time , , CHICAGO, June 15 ... enlarged leg veins as a cosmetic issue without recognizing they can ... their doctors for other health symptoms, Vein Clinics of America is ... from affecting their everyday routine. , , To view the ...
... 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... appointment of Scott Peterson, Ph.D., as Vice President, ... Dr. Peterson will be responsible for overseeing those ... will support the advancement of the Company,s pipeline ...
... June 15 Congressional Quarterly presents a 360-degree look ... follow-on versions of biotech drugs. This CQ Forum will ... groups, and leading researchers regarding the complex structures of ... Will the availability of these products save money for ...
Cached Biology Technology:Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 2Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 3Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 4Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... multitude of cells types. Researchers would like to understand how ... cells that make up the organs and other structures of ... chains of sugars that dangle from proteins on surfaces of ... San Diego, has created synthetic molecules that can stand in ... to direct the process, they report in the Journal ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to John Ellis for his pioneering contributions to biochemistry, ... Professor in the Department of Biological Sciences at the ... of the Springer book How Science Works: Evolution. Dr. ... London, and completed postdoctoral studies at Oxford University. In ...
... centuries-old religious ceremony of an indigenous people in southern Mexico ... of fish, according to researchers from Texas A&M University. ... World, the Zoque people of southern Mexico would venture each ... Cueva del Azufre to implore their deities for a bountiful ...
... most frustrating problems faced by doctors who treat pancreatic cancer ... 38,000 people in the United States die of the disease ... For almost three decades, scientists and physicians have known ... virtually all pancreatic cancers, making it an important target for ...
Cached Biology News:Moved by religion: Mexican cavefish develop resistance to toxin 2Moved by religion: Mexican cavefish develop resistance to toxin 3UNC team discovers promising target for new pancreatic cancer treatments 2
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... optimized for siRNA applications, contains magnetic nanoparticles ... nucleic acid of interest. Exploiting magnetic force ... rapidly drawn towards and delivered into the ... Reagent can be used for adherent cells; ...
Biology Products: